Superior tumor response and survival with triple therapy regimen in hepatocellular carcinoma

Triple therapy regimen (ICI+TKI+TACE) showed higher disease control rate and overall survival compared to other treatments in patients with advanced hepatocellular carcinoma. It had a higher disease control rate than ICI+TACE, ICI+TKI, and TKI+TACE, as well as improved overall survival compared to ICI+TKI and TKI+TACE. However, it also had a greater incidence of adverse events. The combination of immune checkpoint inhibitors, tyrosine kinase inhibitors, and trans-arterial chemoembolization should be considered for select patients with advanced HCC.